Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

Merck & Co’s Jürgen Polifka joins Cardiome

Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess

- PMLiVE

Merck & Co fails to block generic Januvia in India

Court says Glenmark can sell cheap copy of diabetes drug

- PMLiVE

Lilly to invest extra $180m in US insulin manufacturing

Response to growing demand for insulin pens for people with diabetes

- PMLiVE

Janssen’s first-in-class diabetes drug Invokana wins US approval

Will be first SGLT2 inhibitor to reach the market in the States

- PMLiVE

Boehringer – Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

- PMLiVE

EMA launches diabetes drugs safety review

Will investigate pancreatitis risks in two major drug classes

- PMLiVE

Merck Serono signs diabetes partnership with BMS in China

Will co-promote Glucophage (metformin) formulations

- PMLiVE

Improved health communications needed with the UK’s South Asian communities

Red Door Communications launches ethnic minority outreach programme

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links